The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A study published in the journal Science Bulletin was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Chinese Thoracic Oncology Group (CTONG)). In this open ...

Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising Sintilimab, an immunotherapy for cancer treatment in India. This strategic move is ...

The investigational anti-PD-1 antibody sintilimab (Tyvyt, Innovent Biologics and Eli Lilly) has shown that it improves the efficacy of platinum-based chemotherapy in the first-line treatment of ...

Who really benefits from chemotherapy in high-risk localized soft tissue sarcoma? A virtual twin analysis of ISG-STS 1001. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...

Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC). Combining sintilimab and a ...

Fruzaqla and sintilimab combination met the primary endpoint of progression-free survival in the FRUSICA-2 trial for advanced renal cell carcinoma. The trial demonstrated improvements in secondary ...

SAN FRANCISCO and SUZHOU, China, June 20, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The programmed cell death protein 1 (PD-1) inhibitor drug sintilimab in combination with the standard chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) shows significant benefit as ...

Please provide your email address to receive an email when new articles are posted on . “Sintilimab [Tyvyt; Eli Lilly & Co., Innovent Biologics] is a fully human IgG4 monoclonal antibody that blocks ...

Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study. This is an ASCO Meeting Abstract from the 2023 ...